Skip to content

Effect of Myoma Removal on Blood Pressure and Erythropoetin Level

Effect of Myoma Removal on Blood Pressure and Erythropoetin Level

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00898170
Enrollment
28
Registered
2009-05-12
Start date
2008-05-31
Completion date
2009-03-31
Last updated
2009-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Myoma

Keywords

myoma, hypertension, erythropoetin, blood pressure, erythropoetin level

Brief summary

The effect of myoma removal was studied on 28 patients with hypertension and myoma by holter monitoring and erythropoetin level check.

Detailed description

Background: Myoma is the most common gynecoid tumor and produces many vasoactive substances, which may be a cause for secondary hypertension. Early reports suggested the association of myoma and hypertension. We studied the effect of myoma removal on hypertension and erythropoietin level to evaluate this hypothesis. Patients & Methods: In this single centered prospective cohort study, in twenty eight patients who were candidates for myomectomy due to myoma, 24 hour holter monitoring of blood pressure and serum erythropoietin were checked before and 6 weeks after hysterectomy.

Interventions

PROCEDUREmyoma removal

surgical removal of myoma by hysterectomy

Sponsors

Shiraz University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
22 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* candidate for myoma removal by hysterectomy * operable * hysterectomy is indicated

Exclusion criteria

* patient refusal * inoperable patients * other secondary cases of hypertension

Design outcomes

Primary

MeasureTime frame
24 hour holter monitoring of blood pressure6 weeks

Secondary

MeasureTime frame
erythropoetin level6 weeks

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026